Can antipsychotics improve social cognition in patients with schizophrenia?

Katarzyna Kucharska-Pietura, Ann Mortimer, Katarzyna Kucharska-Pietura, Ann Mortimer

Abstract

Social cognition is described as the higher mental processes that are engaged while people store, process, and use social information to make sense of themselves and others. Aspects of social cognition include emotion perception, social cue interpretation, attribution style, and theory of mind, all of which appear disordered in schizophrenia. Such social cognitive deficits are believed to be important predictors of functional outcome in schizophrenia, therefore they may represent a crucial treatment target. Few studies have evaluated the influence of antipsychotic treatment on these deficits. The purpose of this review is to examine the relationship between antipsychotic treatment and social cognition, whether antipsychotics improve social cognitive function, and if so to explore differential medication effects. Comprehensive searches of PsycINFO and MEDLINE/PUBMED were conducted to identify relevant published manuscripts. Fifteen relevant papers published in English were found, describing original studies. On the basis of this review, we have drawn the following conclusions: first, the results do not engender optimism for the possibility that antipsychotic drugs can specifically facilitate social recovery. Second, the actions of antipsychotics on social cognition are inconclusive, due to lack of standardization across research groups, leading to inconsistencies between study designs, methods used, and medication dosages. Third, large-scale longitudinal investigations are needed to explore the unclear relationships between social cognition, symptoms, and functional outcome. Other non-pharmacological treatments focusing on training patients in the social cognitive areas may hold more promise.

References

    1. Penn DL, Corrigan PW, Bentall RP, et al. Social cognition in schizophrenia. Psychol Bull. 1997;121:114–132. doi: 10.1037/0033-2909.121.1.114.
    1. Corrigan PW, Penn DL, editors. Social cognition and schizophrenia. Washington, DC: American Psychological Association; 2001.
    1. Adolphs R. The neurobiology of social cognition. Curr Opin Neurobiol. 2001;11:231–239. doi: 10.1016/S0959-4388(00)00202-6.
    1. Bigelow N, Paardiso S, Adolphs R, et al. Perception of social stimuli in schizophrenia. Schizophr Res. 2006;83:257–267. doi: 10.1016/j.schres.2005.12.856.
    1. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull. 2006;32(Suppl 1):S44–S63. doi: 10.1093/schbul/sbl029.
    1. Brüne M. Emotion recognition, ‘theory of mind’, and social behaviour in schizophrenia. Psychiatry Res. 2005;133:135–147. doi: 10.1016/j.psychres.2004.10.007.
    1. Brüne M, Schaub D. Mental state attribution in schizophrenia: what distinguishes patients with “poor” from patients with “fair” mentalising skills? Eur Psychiatry. 2012;27:358–364. doi: 10.1016/j.eurpsy.2010.10.002.
    1. Ebstein RP, Knafo A, Mankuta D, et al. The contributions of oxytocin and vasopressin pathway genes to human behavior. Horm Behav. 2012;61:359–379. doi: 10.1016/j.yhbeh.2011.12.014.
    1. Domes G, Heinrichs M, Gläscher J, et al. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry. 2007;62:1187–1190. doi: 10.1016/j.biopsych.2007.03.025.
    1. Domes G, Heinrichs M, Michel A, et al. Oxytocin improves “mind-reading” in humans. Biol Psychiatry. 2007;61:31–33. doi: 10.1016/j.biopsych.2006.07.015.
    1. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res. 2011;132:50–53. doi: 10.1016/j.schres.2011.07.027.
    1. Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr Bull. 2011;37:1077–1087. doi: 10.1093/schbul/sbq015.
    1. Ichikawa J, Ishii H, Bonaccorso S, et al. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76:1521–1531. doi: 10.1046/j.1471-4159.2001.00154.x.
    1. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med. 2001;52:503–517. doi: 10.1146/annurev.med.52.1.503.
    1. Akhondzadeh S. The 5-HT hypothesis of schizophrenia. IDrugs. 2001;4:295–300.
    1. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160:13–23. doi: 10.1176/appi.ajp.160.1.13.
    1. Salgado-Pineda P, Delaveau P, Blin O, et al. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol. 2005;28:228–237. doi: 10.1097/01.wnf.0000185824.57690.f0.
    1. Addington J, Addington D. Social and cognitive functioning in psychosis. Schizophr Res. 2008;99:176–181. doi: 10.1016/j.schres.2007.07.004.
    1. Kucharska-Pietura K, David AS, Masiak M, et al. Perception of facial and vocal affect by people with schizophrenia in early and late stages of illness. Br J Psychiatry. 2005;187:523–528. doi: 10.1192/bjp.187.6.523.
    1. Sprong M, Schothorst P, Vos E, et al. Theory of mind in schizophrenia: meta-analysis. Br J Psychiatry. 2007;191:5–13. doi: 10.1192/bjp.bp.107.035899.
    1. Mizrahi R, Korostil M, Starkstein SE, et al. The effect of antipsychotic treatment on Theory of Mind. Psychol Med. 2007;37:595–601. doi: 10.1017/S0033291706009342.
    1. Roncone R, Falloon IR, Mazza M, et al. Is theory of mind in schizophrenia more strongly associated with clinical and social functioning than with neurocognitive deficits? Psychopathology. 2002;35:280–288. doi: 10.1159/000067062.
    1. Gaebel W, Wölwer W. Facial expression and emotional face recognition in schizophrenia and depression. Eur Arch Psychiatry Clin Neurosci. 1992;242:46–52. doi: 10.1007/BF02190342.
    1. Edwards J, Pattison PE, Jackson HJ, et al. Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res. 2001;48:235–253. doi: 10.1016/S0920-9964(00)00099-2.
    1. Trémeau F. Emotion deficits in schizophrenia. Dial Clin Neurosci. 2006;8:58–68.
    1. Penn DL, Ritchie M, Francis J, et al. Social perception in schizophrenia: the role of context. Psychiatry Res. 2002;109:149–159. doi: 10.1016/S0165-1781(02)00004-5.
    1. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301–307. doi: 10.1016/j.biopsych.2004.06.023.
    1. Bleuler EP. Affektivität, Suggestibilität. Halle: Paranoi; 1906.
    1. Harvey PD, Patterson TL, Potter LS, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163:1918–1925. doi: 10.1176/appi.ajp.163.11.1918.
    1. Hempel RJ, Dekker JA, Van Beveren NJ, et al. The effect of antipsychotic medication on facial affect recognition in schizophrenia: a review. Psychiatry Res. 2010;178:1–9. doi: 10.1016/j.psychres.2008.07.025.
    1. Herbener ES, Hill K, Marvin RW, et al. Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia. Am J Psychiatry. 2005;162:1746–1748. doi: 10.1176/appi.ajp.162.9.1746.
    1. Kee KS, Kern RS, Marshall BD, et al. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res. 1998;31:159–165. doi: 10.1016/S0920-9964(98)00026-7.
    1. Penn DL, Keefe RS, Davis SM, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res. 2009;115:17–23. doi: 10.1016/j.schres.2009.08.016.
    1. Lewis SF, Garver DL. Treatment and diagnostic subtype in facial recognition in schizophrenia. J Psychiatry Res. 1995;29:5–11. doi: 10.1016/0022-3956(94)00033-N.
    1. Kucharska-Pietura K, Mortimer A, Tylec A, et al. Social cognition and visual perception in schizophrenia inpatients treated with first- and second-generation antipsychotic drugs. Clin Schizophr Relat Psychoses. 2012;6:14–20. doi: 10.3371/CSRP.6.1.2.
    1. Williams LM, Loughland CM, Green MJ, et al. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry Res. 2003;120:13–27. doi: 10.1016/S0165-1781(03)00166-5.
    1. Brekke JS, DeBonis JA, Graham JW. A latent structure analysis of the positive and negative symptoms in schizophrenia. Compr Psychiatry. 1994;35:252–259. doi: 10.1016/0010-440X(94)90016-7.
    1. Roberts DL, Penn DL, Corrigan P, et al. Antipsychotic medication and social cue recognition in chronic schizophrenia. Psychiatry Res. 2010;178:46–50. doi: 10.1016/j.psychres.2010.04.006.
    1. Green MF, Penn DL, Bentall R, et al. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008;34:1211–1220. doi: 10.1093/schbul/sbm145.
    1. Combs DR, Penn DL, Michael CO, et al. Perceptions of hostility by persons with and without persecutory delusions. Cogn Neuropsychiatry. 2009;14:30–52. doi: 10.1080/13546800902732970.
    1. Bellack AS, Schooler NR, Marder SR, et al. Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry. 2004;161:364–367. doi: 10.1176/appi.ajp.161.2.364.
    1. Sergi MJ, Green MF, Widmark C, et al. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007;164:1585–1592. doi: 10.1176/appi.ajp.2007.06091515.
    1. Machado de Sousa JP, Hallak JE. Neurocognitive functioning and facial affect recognition in treatment-resistant schizophrenia treated with clozapine. Schizophr Res. 2008;106:371–372. doi: 10.1016/j.schres.2008.09.012.
    1. Littrell KH, Petty RG, Hilligoss NM, et al. Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine. Schizophr Res. 2004;66:201–202. doi: 10.1016/S0920-9964(03)00185-3.
    1. Savina I, Beninger RJ. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications. Schizophr Res. 2007;94:128–138. doi: 10.1016/j.schres.2007.04.010.
    1. Fakra E, Salgado-Pineda P, Besnier N, et al. Risperidone versus haloperidol for facial affect recognition in schizophrenia: findings from a randomised study. World J Biol Psychiatry. 2009;10:719–728. doi: 10.1080/15622970701432536.
    1. Heidbreder CA, Foxton R, Cilia J, et al. Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacol Berl. 2001;156:338–351. doi: 10.1007/s002130100760.
    1. Fakra E, Kaladjian A, Adida M, et al. Schizophrenia, psychotropic drugs and cognition. Encephale. 2011;37(Suppl 2):S137–S142. doi: 10.1016/S0013-7006(11)70041-0.
    1. Kerr SL, Neale JM. Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance? J Abnorm Psychol. 1993;102:312–318. doi: 10.1037/0021-843X.102.2.312.
    1. Sachs G, Winklbaur B, Jagsch R, et al. Training of affect recognition (TAR) in schizophrenia–impact on functional outcome. Schizophr Res. 2012;138:262–267. doi: 10.1016/j.schres.2012.03.005.
    1. Combs DR, Adams SD, Penn DL, et al. Social cognition and interaction training (SCIT) for inpatients with schizophrenia spectrum disorders: preliminary findings. Schizophr Res. 2007;91:112–116. doi: 10.1016/j.schres.2006.12.010.
    1. Roberts DL, Penn DL. Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res. 2009;166:141–147. doi: 10.1016/j.psychres.2008.02.007.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit